2017 American Transplant Congress
One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial.
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has now been widely accepted in kidney transplant field. However, the optimal dosage for TACER is still not known.Patients…2017 American Transplant Congress
Tacrolimus Pharmacogenomics: Association of Genetic Variants with Clinical Factors Including Tacrolimus Requirement, Clearance, Intraindividual Variability, and Coefficient Variation.
Background: Tacrolimus, which plays a backbone in immunosuppressive therapy, has a different effect in absorption according to intraindividual and interindividual variability, and it is a…2017 American Transplant Congress
A Critical Analysis of Equations for MPA Exposure in Patients Under EC-MPS and Tacrolimus.
Hospital das Clinicas FMUSP, Sao Paulo, Brazil
Mycophenolic acid(MPA) PK, from enteric-coated mycophenolate sodium(EC-MPS) has a broad range of Tmax avoiding the use a single concentration to calculate the area-under-the-time-concentration curve(AUC). Either…2016 American Transplant Congress
Nuclear Factor of Activated T-Cells Post-Renal Transplant.
Background: Nuclear Factor of Activated T-cells (NFAT1) is a transcription factor regulating the expression of key targets involved with cellular immune function. Calcineurin is a…2016 American Transplant Congress
Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.
Pharmacokinetic (PK) data show reduced mycophenolic acid levels in transplant recipients taking mycophenolate mofetil (MMF) and proton pump inhibitors (PPIs) concomitantly. MMF dosing is not…2016 American Transplant Congress
Late Renal Allograft Rejection Is Predicted by High Intrapatient Variability of Tacrolimus Levels.
Imperial College Renal and Transplant Centre, Imperial College NHS Trust, London, United Kingdom.
IntroductionNonadherence to immunosuppressive medication is associated with rejection and graft loss. We have previously shown that intrapatient variability (IPV) of tacrolimus trough levels between 6-12…2016 American Transplant Congress
Factors and Outcomes Associated with Daptomycin Non-Susceptible Enterococcal Infections in Solid Organ Transplant Recipients.
Background: Daptomycin non-susceptible enterococcal (DNSE) infections are associated with poor outcomes. Information regarding factors and outcomes of DNSE in solid organ transplant (SOT) recipients (SOTR)…2016 American Transplant Congress
Plasma Alemtuzumab Levels Show Great Interpatient Variability, but Are Not Associated with Late Acute Rejection in Simultaneous Pancreas-Kidney Recipients.
Introduction: Alemtuzumab induction followed by a steroid-free, tacrolimus (Tac) and mycophenolate mofetil (MMF) based regimen effectively prevented acute rejection after simultaneous pancreas-kidney transplantation (SPKT). Acute…2016 American Transplant Congress
Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.
1SparTacus Study Group, Cologne, Germany; 2Novartis Pharma GmbH, Nuernberg, Germany.
Background: There is very limited evidence on the pharmacokinetic (PK) and clinical outcomes, comparing a generic tacrolimus with the standard reference drug in transplant (Tx)…2016 American Transplant Congress
Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients.
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- Next Page »